Jon P Williams, Justin R Abbatemarco, Jonathan J Galli, Stefanie J Rodenbeck, Lisa K Peterson, Thomas R Haven, Meagan Street, John W Rose, John E Greenlee, M Mateo Paz Soldan, Stacey L Clardy
{"title":"ELISA法检测水通道蛋白-4自身抗体:一种常用检测方法的回顾性分析。","authors":"Jon P Williams, Justin R Abbatemarco, Jonathan J Galli, Stefanie J Rodenbeck, Lisa K Peterson, Thomas R Haven, Meagan Street, John W Rose, John E Greenlee, M Mateo Paz Soldan, Stacey L Clardy","doi":"10.1155/2021/8692328","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Aquaporin-4 (AQP4) serum autoantibodies are detected by a variety of methods. The highest sensitivity is achieved with cell-based assays, but the enzyme-linked immunosorbent assay (ELISA) is still commonly utilized by clinicians worldwide.</p><p><strong>Methods: </strong>We performed a retrospective review to identify all patients at the University of Utah who had AQP4 ELISA testing at ARUP Laboratories from 2010 to 2017. We then reviewed their diagnostic evaluation and final diagnosis based on the ELISA titer result.</p><p><strong>Results: </strong>A total of 750 tests for the AQP4 ELISA were analyzed, and 47 unique patients with positive titers were identified. Less than half of these patients (49%) met the clinical criteria for neuromyelitis optica spectrum disorder (NMOSD). In cases of low positive titers (3.0-7.9 U/mL, <i>n</i> = 19), the most common final diagnosis was multiple sclerosis (52.6%). In the moderate positive cohort (8.0-79.9 U/mL, <i>n</i> = 14), only a little more than half the cohort (64.3%) had NMOSD. In cases with high positives (80-160 U/mL, <i>n</i> = 14), 100% of patients met clinical criteria for NMOSD.</p><p><strong>Conclusions: </strong>Our data illustrates diagnostic uncertainty associated with the AQP4 ELISA, an assay that is still commonly ordered by clinicians despite the availability of more sensitive and specific tests to detect AQP4 autoantibodies in patients suspected of having NMOSD. In particular, low positive titer AQP4 ELISA results are particularly nonspecific for the diagnosis of NMOSD. The importance of accessibility to both sensitive and specific AQP4 testing cannot be overemphasized in clinical practice.</p>","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2021 ","pages":"8692328"},"PeriodicalIF":2.2000,"publicationDate":"2021-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492278/pdf/","citationCount":"7","resultStr":"{\"title\":\"Aquaporin-4 Autoantibody Detection by ELISA: A Retrospective Characterization of a Commonly Used Assay.\",\"authors\":\"Jon P Williams, Justin R Abbatemarco, Jonathan J Galli, Stefanie J Rodenbeck, Lisa K Peterson, Thomas R Haven, Meagan Street, John W Rose, John E Greenlee, M Mateo Paz Soldan, Stacey L Clardy\",\"doi\":\"10.1155/2021/8692328\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Aquaporin-4 (AQP4) serum autoantibodies are detected by a variety of methods. The highest sensitivity is achieved with cell-based assays, but the enzyme-linked immunosorbent assay (ELISA) is still commonly utilized by clinicians worldwide.</p><p><strong>Methods: </strong>We performed a retrospective review to identify all patients at the University of Utah who had AQP4 ELISA testing at ARUP Laboratories from 2010 to 2017. We then reviewed their diagnostic evaluation and final diagnosis based on the ELISA titer result.</p><p><strong>Results: </strong>A total of 750 tests for the AQP4 ELISA were analyzed, and 47 unique patients with positive titers were identified. Less than half of these patients (49%) met the clinical criteria for neuromyelitis optica spectrum disorder (NMOSD). In cases of low positive titers (3.0-7.9 U/mL, <i>n</i> = 19), the most common final diagnosis was multiple sclerosis (52.6%). In the moderate positive cohort (8.0-79.9 U/mL, <i>n</i> = 14), only a little more than half the cohort (64.3%) had NMOSD. In cases with high positives (80-160 U/mL, <i>n</i> = 14), 100% of patients met clinical criteria for NMOSD.</p><p><strong>Conclusions: </strong>Our data illustrates diagnostic uncertainty associated with the AQP4 ELISA, an assay that is still commonly ordered by clinicians despite the availability of more sensitive and specific tests to detect AQP4 autoantibodies in patients suspected of having NMOSD. In particular, low positive titer AQP4 ELISA results are particularly nonspecific for the diagnosis of NMOSD. The importance of accessibility to both sensitive and specific AQP4 testing cannot be overemphasized in clinical practice.</p>\",\"PeriodicalId\":46096,\"journal\":{\"name\":\"Multiple Sclerosis International\",\"volume\":\"2021 \",\"pages\":\"8692328\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2021-09-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492278/pdf/\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Multiple Sclerosis International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2021/8692328\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2021/8692328","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 7
摘要
目的:采用多种方法检测水通道蛋白-4 (AQP4)血清自身抗体。以细胞为基础的测定方法灵敏度最高,但酶联免疫吸附测定(ELISA)仍被世界各地的临床医生普遍使用。方法:我们对2010年至2017年在ARUP实验室进行AQP4酶联免疫吸附试验的犹他大学所有患者进行回顾性研究。然后我们回顾了他们的诊断评估和最终诊断基于ELISA滴度结果。结果:共分析750例AQP4酶联免疫吸附试验,鉴定出47例独特的滴度阳性患者。这些患者中不到一半(49%)符合视神经脊髓炎谱系障碍(NMOSD)的临床标准。在低阳性滴度(3.0-7.9 U/mL, n = 19)的病例中,最常见的最终诊断是多发性硬化症(52.6%)。在中度阳性队列(8.0-79.9 U/mL, n = 14)中,只有略多于一半的队列(64.3%)发生NMOSD。在高阳性(80-160 U/mL, n = 14)的病例中,100%的患者符合NMOSD的临床标准。结论:我们的数据说明了与AQP4 ELISA相关的诊断不确定性,尽管在疑似患有NMOSD的患者中有更敏感和特异性更高的AQP4自身抗体检测方法,但临床医生仍然经常订购这种检测方法。特别是,低效价AQP4 ELISA结果对NMOSD的诊断尤其无特异性。在临床实践中,获得敏感性和特异性AQP4检测的重要性再怎么强调也不为过。
Aquaporin-4 Autoantibody Detection by ELISA: A Retrospective Characterization of a Commonly Used Assay.
Objective: Aquaporin-4 (AQP4) serum autoantibodies are detected by a variety of methods. The highest sensitivity is achieved with cell-based assays, but the enzyme-linked immunosorbent assay (ELISA) is still commonly utilized by clinicians worldwide.
Methods: We performed a retrospective review to identify all patients at the University of Utah who had AQP4 ELISA testing at ARUP Laboratories from 2010 to 2017. We then reviewed their diagnostic evaluation and final diagnosis based on the ELISA titer result.
Results: A total of 750 tests for the AQP4 ELISA were analyzed, and 47 unique patients with positive titers were identified. Less than half of these patients (49%) met the clinical criteria for neuromyelitis optica spectrum disorder (NMOSD). In cases of low positive titers (3.0-7.9 U/mL, n = 19), the most common final diagnosis was multiple sclerosis (52.6%). In the moderate positive cohort (8.0-79.9 U/mL, n = 14), only a little more than half the cohort (64.3%) had NMOSD. In cases with high positives (80-160 U/mL, n = 14), 100% of patients met clinical criteria for NMOSD.
Conclusions: Our data illustrates diagnostic uncertainty associated with the AQP4 ELISA, an assay that is still commonly ordered by clinicians despite the availability of more sensitive and specific tests to detect AQP4 autoantibodies in patients suspected of having NMOSD. In particular, low positive titer AQP4 ELISA results are particularly nonspecific for the diagnosis of NMOSD. The importance of accessibility to both sensitive and specific AQP4 testing cannot be overemphasized in clinical practice.
期刊介绍:
Multiple Sclerosis International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to all aspects of multiple sclerosis, including clinical neurology, neuroimaging, neuropathology, therapeutics, genetics, neuroimmunology, biomarkers, psychology and neurorehabilitation.